ProMIS Neurosciences Inc. (PMN)
Nasdaq: PMN · Pharmaceutical Preparations · Toronto, ON · filing with the SEC since 2006
Who owns ProMIS Neurosciences Inc.
As filed with the SECHolders of 5% or more
10
Fan Yu holds 17% of Common Shares, no par value per share, as its SCHEDULE 13D/A filed Feb 5, 2026 says.
Directors and officers
12
report now, of 16 people on the record since 2022. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 10 named at left.
Holders of 5% or moreshare of the class, as filed
Fan Yu
SCHEDULE 13D/A · filed Feb 5, 2026 · Common Shares, no par value per share · 11.3% in Feb 2, 2026
Jeremy M. Sclar
SCHEDULE 13G/A · filed Oct 15, 2025 · Common Shares, No Par Value per Share
Janus Henderson Group PLC
SCHEDULE 13G · filed Apr 7, 2026 · Common Shares
Shaf QIC LLC
SCHEDULE 13G/A · filed Jul 31, 2025 · Common Shares
Deep Track Capital, LP
SCHEDULE 13G · filed Feb 6, 2026 · Common Shares, no par value per share
Trails Edge Capital Partners, LP
SCHEDULE 13G · filed Feb 10, 2026 · Common Shares, no par value per share
Wellington Biomedical Innovation Master Investors (Cayman) II, L.P.
SCHEDULE 13G/A · filed Aug 13, 2026 · Common Stock · 9.99% in Mar 18, 2026
Wellington Management Group LLP
SCHEDULE 13G/A · filed Aug 13, 2026 · Common Stock · 10% in May 15, 2026
Sphera Funds Management Ltd.
SCHEDULE 13G/A · filed Feb 5, 2026 · Common Shares, no par value per share · 5.51% in Oct 23, 2025
Great Point Partners, LLC
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Shares, No Par Value per Share · 9.99% in May 15, 2026
Michael S. Gordon
SCHEDULE 13G/A · filed May 7, 2026 · Common Shares, No Par Value · reported falling below 5%, from 9% in Aug 14, 2025
Armistice Capital, LLC
SCHEDULE 13G/A · filed Feb 17, 2026 · Common Shares, no par value per share · reported falling below 5%, from 5.53% in Nov 14, 2025
What PMN reports owning in othersstakes of 5% or more, and other ties
1 subsidiary in 1 country, from the list filed with the 10-K filed Mar 25, 2026.
Insider tradesForm 4
0sales
10purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$400,000bought, in dollars
Open-market trades on Form 4 from Nov 6, 2025 to Nov 6, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 6, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window5 of 31 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Williams Eugene | Chairman and CEO | 0 | $0 | 0 | 6 | $200,000 |
| Kaplan Johanne | Chief Development Officer | 0 | $0 | 0 | 2 | $100,000 |
| Cashman Neil | Chief Scientific Officer | 0 | $0 | 0 | 1 | $0 |
| Kirwin Patrick D. | director | 0 | $0 | 0 | 1 | $0 |
| Yu Fan | 10% owner | 0 | $0 | 0 | 1 | $8.5M |